Vaccine Platform

About Biolingus

Biolingus is pioneering a novel drug delivery platform focused on the sublingual (under-the-tongue) administration of large molecule drugs, including peptides, proteins, and vaccines. Its core technology is designed to protect biologics from degradation in the gut and facilitate absorption directly into the bloodstream via the oral mucosa, potentially eliminating the need for painful and costly injections. The company is advancing a pipeline of internal and partnered programs, targeting significant markets in diabetes, obesity, and immunology. As a private, pre-revenue entity, Biolingus's success hinges on validating its platform in clinical trials and securing strategic partnerships to fund development and commercialization.

About Omios Biologics

Omios Biologics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company's core innovation is a patented oncolytic vaccinia virus platform designed with a built-in biomarker for selectivity, aiming to overcome the efficacy-safety trade-offs of earlier OV therapies. With a leadership team possessing deep expertise in virology and biotech, Omios is developing a pipeline of OV therapies, cancer vaccines, and gene delivery vectors, targeting a significant market opportunity in oncology with a focus on combination treatments.

Therapeutic Areas

Other Infectious Disease Drugs